Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
45.3
USD
|
+1.98%
|
|
-1.93%
|
-24.71%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,735
|
7,175
|
8,357
|
10,938
|
8,241
|
-
|
-
|
Enterprise Value (EV)
1 |
3,233
|
6,446
|
7,855
|
9,959
|
7,313
|
7,406
|
7,036
|
P/E ratio
|
-22
x
|
-34
x
|
-35.7
x
|
-40.9
x
|
-41.9
x
|
-141
x
|
75.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
49.4
x
|
79.9
x
|
71.4
x
|
38.4
x
|
14.1
x
|
7.66
x
|
5.01
x
|
EV / Revenue
|
42.7
x
|
71.8
x
|
67.1
x
|
34.9
x
|
12.5
x
|
6.88
x
|
4.28
x
|
EV / EBITDA
|
-14.6
x
|
-17.9
x
|
-17.7
x
|
-25.4
x
|
-22.9
x
|
-115
x
|
33.3
x
|
EV / FCF
|
-12
x
|
-26.6
x
|
-33.1
x
|
-24.1
x
|
-22.2
x
|
-116
x
|
40.7
x
|
FCF Yield
|
-8.31%
|
-3.76%
|
-3.02%
|
-4.15%
|
-4.51%
|
-0.86%
|
2.46%
|
Price to Book
|
26.7
x
|
30.5
x
|
-
|
17.5
x
|
6.49
x
|
6.26
x
|
4.36
x
|
Nbr of stocks (in thousands)
|
132,638
|
153,946
|
167,403
|
181,789
|
181,911
|
-
|
-
|
Reference price
2 |
28.16
|
46.61
|
49.92
|
60.17
|
45.30
|
45.30
|
45.30
|
Announcement Date
|
3/18/21
|
3/18/22
|
3/30/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
75.68
|
89.79
|
117
|
285.1
|
585.2
|
1,076
|
1,644
|
EBITDA
1 |
-220.8
|
-360.6
|
-443.2
|
-392.1
|
-319.9
|
-64.2
|
211.6
|
EBIT
1 |
-229.2
|
-373
|
-455.8
|
-412.6
|
-335.4
|
-101.4
|
222.4
|
Operating Margin
|
-302.87%
|
-415.44%
|
-389.58%
|
-144.69%
|
-57.32%
|
-9.42%
|
13.53%
|
Earnings before Tax (EBT)
1 |
-307.6
|
-386.2
|
-445.7
|
-520.1
|
-317.1
|
-90.51
|
234
|
Net income
1 |
-303.5
|
-386.2
|
-446.3
|
-518.3
|
-316
|
-92.46
|
211.5
|
Net margin
|
-401.02%
|
-430.12%
|
-381.48%
|
-181.75%
|
-54%
|
-8.59%
|
12.86%
|
EPS
2 |
-1.280
|
-1.370
|
-1.400
|
-1.470
|
-1.081
|
-0.3208
|
0.5966
|
Free Cash Flow
1 |
-268.8
|
-242.4
|
-237
|
-413.4
|
-330.1
|
-63.63
|
172.9
|
FCF margin
|
-355.14%
|
-269.92%
|
-202.57%
|
-144.97%
|
-56.41%
|
-5.91%
|
10.51%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
81.71%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
81.73%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/21
|
3/18/22
|
3/30/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
16.88
|
39
|
40.83
|
11.97
|
36.34
|
73.33
|
96.01
|
79.46
|
144.3
|
125.1
|
131.7
|
178.7
|
178.9
|
EBITDA
1 |
-82.13
|
-114.2
|
-
|
-116.1
|
-
|
-
|
-53.64
|
-
|
-63.85
|
-120.6
|
-107.9
|
-93.5
|
-77.21
|
EBIT
1 |
-86.77
|
-117.5
|
-76
|
-125.5
|
-106.9
|
-104.3
|
-56.82
|
-141
|
-60.35
|
-87.05
|
-100.8
|
-91.47
|
-87.64
|
Operating Margin
|
-513.98%
|
-301.22%
|
-186.16%
|
-1,048.6%
|
-294.09%
|
-142.25%
|
-59.18%
|
-177.43%
|
-41.83%
|
-69.59%
|
-76.51%
|
-51.19%
|
-48.98%
|
Earnings before Tax (EBT)
1 |
-124.8
|
-88.33
|
-41.09
|
-193.1
|
-112
|
-198.8
|
-62.5
|
-146.8
|
-69.29
|
-90.67
|
-98.08
|
-84.61
|
-91.64
|
Net income
1 |
-124.8
|
-88.33
|
-41.09
|
-193.2
|
-112.1
|
-199.1
|
-62.21
|
-144.8
|
-69.04
|
-90.46
|
-97.69
|
-83.82
|
-91.79
|
Net margin
|
-738.96%
|
-226.53%
|
-100.64%
|
-1,614.13%
|
-308.51%
|
-271.55%
|
-64.79%
|
-182.24%
|
-47.86%
|
-72.32%
|
-74.16%
|
-46.9%
|
-51.3%
|
EPS
2 |
-0.4300
|
-0.3000
|
-0.1300
|
-0.6200
|
-0.3400
|
-0.5700
|
-0.1700
|
-0.4000
|
-0.1783
|
-0.2792
|
-0.2919
|
-0.2366
|
-0.2475
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/16/21
|
3/18/22
|
6/1/22
|
2/17/23
|
5/18/23
|
8/15/23
|
11/20/23
|
3/11/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
502
|
729
|
501
|
979
|
928
|
835
|
1,205
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-269
|
-242
|
-237
|
-413
|
-330
|
-63.6
|
173
|
ROE (net income / shareholders' equity)
|
-284%
|
-103%
|
-59.1%
|
-51.9%
|
-32.9%
|
-5.7%
|
13.9%
|
ROA (Net income/ Total Assets)
|
-44.3%
|
-42%
|
-36.4%
|
-32.6%
|
-26.4%
|
-3.15%
|
11.1%
|
Assets
1 |
684.9
|
919.7
|
1,225
|
1,590
|
1,196
|
2,937
|
1,911
|
Book Value Per Share
2 |
1.050
|
1.530
|
-
|
3.440
|
6.980
|
7.230
|
10.40
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
45.7
|
43.9
|
35.7
|
20.1
|
41.9
|
42.8
|
37.1
|
Capex / Sales
|
60.45%
|
48.9%
|
30.54%
|
7.04%
|
7.16%
|
3.98%
|
2.25%
|
Announcement Date
|
3/18/21
|
3/18/22
|
3/30/23
|
3/11/24
|
-
|
-
|
-
|
Last Close Price
45.3
USD Average target price
86.33
USD Spread / Average Target +90.57% Consensus |
1st Jan change
|
Capi.
|
---|
| -24.71% | 8.24B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|